Tissue Diagnostics Market by Product (Consumables [Antibodies, Kits, Reagents, Probes], Instruments [Systems, Scanner], Software, Services), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Global Forecast to 2030

Market Size
$6.74B
MARKET SIZE, 2025
Projected Market Size
$10.86B
MARKET SIZE, 2030
CAGR
10.0%
CAGR (2025-2030)
Forecast Period
2025-2030
FORECAST PERIOD

OVERVIEW

tissue-diagnostics-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global Tissue Diagnostics market, valued at USD 6.19 billion in 2024, stood at USD 6.74 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of USD 10.86 billion by the end of the period. The market growth is driven by the rising incidence of cancer and the growing demand for digital pathology, which are fueling the need for more accurate and high-throughput tissue-based diagnostics. Additionally, increasing healthcare expenditure and wider availability of reimbursements are enabling broader access to advanced diagnostic technologies, while the expansion of private diagnostic centers is supporting the adoption of standardized and automated laboratory workflows. Collectively, these factors are driving higher demand for tissue diagnostics, enhancing early disease detection, and improving overall patient management across healthcare systems.

KEY TAKEAWAYS

  • MARKET SNAPSHOT:
    Base Year Market Size (2024): USD 6.19 Billion
    Current Market Size (2025): USD 6.74 Billion
    Forecast Market Size (2030): USD 10.86 Billion
    CAGR (2025–2030): 10.0%
  • SEGMENT LEADERSHIP:
    Regional Leader: North America leads the market, while Asia Pacific is expected to register the fastest growth.
    Product Leader: Consumables account for the largest share of the tissue diagnostics market.
    Technology Leader: Immunohistochemistry (IHC) leads the market due to its high specificity, sensitivity, and versatility in detecting protein biomarkers.
    Disease Type Leader: Breast cancer holds the largest share of the tissue diagnostics market.
    End User Leader: Hospitals remain the leading end users due to high patient volumes and increasing adoption of advanced tissue diagnostic solutions.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    F. Hoffmann-La Roche Ltd., Danaher Corporation, and PHC Holdings Corporation are key players in the tissue diagnostics market. These companies are pursuing partnerships, collaborations, strategic investments, and product innovations to strengthen their product portfolios, manufacturing capabilities, automation technologies, and global distribution networks.

The tissue diagnostics market is poised for robust growth in the coming years, driven by the rising incidence of cancer and increasing demand for accurate and timely disease diagnosis. Advanced technologies such as immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and multiplex staining systems are being increasingly adopted to improve biomarker detection, support personalized treatment decisions, and enhance patient outcomes. The growing number of private diagnostic centers, coupled with increasing healthcare expenditure and greater access to reimbursements, is further accelerating market adoption. In addition, ongoing technological advancements and the expansion of laboratory infrastructure are improving workflow efficiency, reproducibility, and the overall reliability of tissue diagnostic solutions.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The tissue diagnostics market is experiencing notable shifts due to the increasing prevalence of cancer, rising focus on early and accurate disease detection, and continuous advancements in diagnostic technologies. Hospitals, research laboratories, and pharmaceutical companies form the primary customer base for tissue diagnostics solutions. Key trends, such as the adoption of automated immunohistochemistry (IHC) and in situ hybridization (ISH) platforms, integration of digital pathology, and demand for high-throughput and standardized workflows, are reshaping laboratory operations. These technological developments and workflow optimizations influence the procurement of consumables, instruments, software, and diagnostic services, driving market growth and redefining competitive dynamics in the tissue diagnostics sector.

tissue-diagnostics-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising incidence of cancer
  • Growing demand for digital pathology
RESTRAINTS
Impact
Level
  • High cost of tissue diagnostic systems
  • Stringent regulatory requirements
OPPORTUNITIES
Impact
Level
  • High growth potential of emerging economies
  • Growing preference for personalized medicines
CHALLENGES
Impact
Level
  • Shortage of skilled professionals
  • Availability of refurbished products

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising incidence of cancer

The rising incidence of cancer is a key factor fueling growth in the tissue diagnostics market. As cancer prevalence increases globally, the demand for accurate and timely diagnosis of various tumor types has grown substantially. Early detection through tissue-based testing is critical for effective treatment planning, personalized therapies, and improved patient outcomes. This trend is driving hospitals, research laboratories, and diagnostic centers to adopt advanced tissue diagnostic solutions, including immunohistochemistry, in situ hybridization, and digital pathology systems. Consequently, the expanding patient population and growing focus on cancer management are directly supporting the adoption of innovative tissue diagnostics, positioning it as a high-priority area in healthcare.

Restraint: High cost of tissue diagnostic systems

The high cost of tissue diagnostic systems remains a significant restraint for market growth. Advanced instruments, such as automated IHC stainers, digital pathology scanners, and tissue-processing systems, often involve substantial upfront investments, making them less accessible to smaller laboratories and clinics, particularly in developing regions. In addition to equipment costs, maintenance, calibration, and consumable requirements further increase the overall expenditure. These financial barriers can slow adoption rates, limit the deployment of cutting-edge technologies, and pose challenges for healthcare providers aiming to balance diagnostic accuracy with cost efficiency.

Opportunity: High growth potential of emerging economies

Emerging economies present substantial growth opportunities for the tissue diagnostics market. Increasing healthcare investments, expanding hospital infrastructure, and rising awareness of cancer screening and early diagnosis are driving demand for advanced diagnostic solutions in these regions. As governments and private players focus on improving access to quality healthcare, there is a growing need for modern tissue diagnostic systems, consumables, and related services. Additionally, the adoption of newer technologies, such as digital pathology and automated IHC platforms, is gradually increasing, creating opportunities for market expansion and strategic partnerships in high-growth markets across Asia Pacific, Latin America, and the Middle East & Africa.

Challenge: Shortage of skilled professionals

A key challenge for the tissue diagnostics market is the shortage of skilled professionals, including trained pathologists and laboratory technicians. This scarcity can lead to delays in sample analysis, inconsistencies in diagnostic results, and increased workload on existing staff. The complexity of advanced diagnostic technologies, such as automated IHC systems and digital pathology platforms, further exacerbates the need for specialized training. Addressing this challenge requires investment in workforce development, training programs, and collaboration with academic and professional institutions to ensure a steady supply of qualified personnel capable of operating sophisticated tissue diagnostic workflows efficiently.

TISSUE DIAGNOSTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Offers integrated tissue diagnostics and digital pathology solutions using VENTANA series scanners for whole-slide imaging and quantitative IHC biomarker analysis (e.g., PD-L1 scoring in NSCLC) High-quality digitized images, faster and reproducible biomarker scoring, optimized workflow efficiency, supports telepathology, reduces manual errors
Provides complete pathology workflow solutions including sample preparation, automated staining (BOND RX/RXm), and imaging for IHC, ISH, and immunofluorescence applications Standardized staining, high-throughput processing, reduced manual errors, flexible protocols, supports research and diagnostic workflows
Supplies automated instruments for tissue processing: microtomes, tissue processors, embedding systems, and staining platforms to standardize histology workflows Consistent tissue preparation, reduced labor and turnaround time, improved assay reliability, supports large-scale laboratory workflows
Offers automated IHC/ISH staining instruments (Dako Omnis), reagents, and multiplex workflows for spatial biomarker analysis and companion diagnostics Multiplex testing on single instrument, consistent results with ready-to-use reagents, high-throughput biomarker analysis, supports companion diagnostics

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The tissue diagnostics market serves a diverse range of end users, including hospitals, research laboratories, pharmaceutical companies, and contract research organizations. Testing primarily focuses on cancer and other disease diagnostics, with emerging applications in personalized medicine and biomarker identification. The uptake of tissue diagnostics is being driven by advancements in automated tissue processing, digital pathology platforms, and high-throughput immunohistochemistry workflows, which improve accuracy, consistency, and laboratory efficiency. Increasing regulatory approvals, hospital accreditation standards, and preventive healthcare initiatives are fostering innovation and expanding clinical applications across different end-user segments.

tissue-diagnostics-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

tissue-diagnostics-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Tissue Diagnostics Market, By Product & Service

The tissue diagnostics market is segmented into consumables, instruments, software, and services, with consumables accounting for the largest share. Consumables include antibodies, IHC and ISH kits, reagents, probes, and other essential materials that are used repeatedly across diagnostic workflows. Their recurring use, combined with the rising incidence of cancer, the growing demand for precise biomarker testing, and the increasing number of private diagnostic centers, is driving strong market growth. Instruments, software, and services support laboratory operations and workflow efficiency, but the consistent demand for high-quality consumables continues to make this segment the primary revenue driver in the tissue diagnostics market.

Tissue Diagnostics Market, By Technology

Based on technology, the tissue diagnostics market is segmented into immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, special staining, and other technologies, with IHC leading the market. IHC remains dominant due to its high specificity, sensitivity, and versatility in detecting protein biomarkers across different tissue types. Automated staining systems, multiplex IHC platforms, and high-throughput workflows have increased efficiency and reproducibility, enabling laboratories to handle larger sample volumes with consistent results. The integration of digital imaging and advanced data management further enhances accuracy and reduces human variability, reinforcing IHC’s position as the most widely adopted and fastest-growing technology in tissue diagnostics.

Tissue Diagnostics Market, By Disease Type

The tissue diagnostics market is segmented by disease type into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer (NSCLC), and other disease types. Among these, breast cancer holds the largest share of the market. This is attributed to the rising global incidence of breast cancer, increased focus on early detection, and the growing utilization of biomarker-based tissue diagnostic assays. Technological advancements in tissue profiling and targeted diagnostics are further driving the adoption of tissue-based tests for breast cancer, making it the leading contributor to market growth.

Tissue Diagnostics Market, By End User

The tissue diagnostics market caters to a wide array of end users, including hospitals, research laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users. Hospitals remain a key end user in the tissue diagnostics market, as they handle high patient volumes and require accurate tissue-based diagnostics for effective clinical decision-making and treatment planning. The increasing prevalence of cancer has heightened the need for timely and precise tissue analysis, driving the adoption of advanced reagents and automated instruments. Moreover, hospitals are increasingly integrating standardized workflows and high-throughput diagnostic platforms to improve efficiency, ensure consistency in results, and support personalized medicine initiatives, reinforcing their central role in the market.

REGION

North America accounted for the largest share of the global tissue diagnostics market during the forecast period.

The tissue diagnostics market in North America is expanding, driven by increasing awareness of cancer detection, rising adoption of preventive healthcare programs, and growing implementation of advanced technologies such as automated tissue processors, digital pathology scanners, and high-throughput immunohistochemistry platforms. Furthermore, the region benefits from a well-established healthcare infrastructure, substantial healthcare expenditure, and supportive initiatives from both government and private sectors to enhance diagnostic capabilities, collectively fueling the growth of the tissue diagnostics market.

tissue-diagnostics-market Region

TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX

F. Hoffmann-La Roche Ltd. (Switzerland) holds a leading position in the tissue diagnostics market, known for its comprehensive portfolio of instruments, reagents, and software solutions that enable accurate and standardized tissue-based testing. The company’s VENTANA and BenchMark systems are widely adopted across pathology laboratories for immunohistochemistry (IHC) and in situ hybridization (ISH) applications, ensuring reproducibility and workflow efficiency. Roche’s focus on automation, quality, and integration has positioned it as a key enabler of advanced diagnostic practices, supporting faster turnaround times and improved clinical decision-making.

tissue-diagnostics-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size Value in 2024 USD 6.2 Billion
Revenue Forecast in 2030 USD 10.86 Billion
Growth Rate CAGR of 10.0% from 2025-2030
Years Considered 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Million), Volume (Million)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered
  • By product & service (consumables, instruments, software, and services)
  • Technology (immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, special staining, and other technologies)
  • Disease type (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, other disease types)
  • End user [hospitals, research laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users]
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

WHAT IS IN IT FOR YOU: TISSUE DIAGNOSTICS MARKET REPORT CONTENT GUIDE

tissue-diagnostics-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Product Analysis Product matrix, which provides a detailed comparison of the product portfolio of each company in the tissue diagnostics market Enables easy comparison of competitors’ offerings, helping identify gaps, overlaps, and differentiation opportunities.
Company Information Additional five company profiles of players operating in the tissue diagnostics market Provides insights into competitors’ strategies, innovation focus, and partnerships, supporting strategic planning.
Geographic Analysis Additional country-level analysis of the tissue diagnostics market Guides market entry, localization, and targeted launch strategies by highlighting regional demand and opportunities.

RECENT DEVELOPMENTS

  • September 2025 : Leica Biosystems (subsidiary of Danaher Corporation) (US) and Moffitt Cancer Center, one of the nation’s top cancer hospitals and a leader in cancer research, expanded their partnership to accelerate the adoption of digital pathology across the state. This strategic partnership marked Florida’s first large-scale implementation of digital pathology technology, aimed at improving speed, precision, and access to pathology services.
  • June 2025 : Sakura Finetek USA (US) launched two new ready-to-use antibodies for the Tissue-Tek Genie Advanced Staining System. 
  • March 2025 : Epredia (subsidiary of PHC Holdings Corporation (Japan) received US FDA 510(k) clearance for its E1000 Dx Digital Pathology Solution, developed to enhance laboratory workflows in cancer diagnostics. 
  • January 2025 : F. Hoffmann-La Roche Ltd. (Switzerland) received US FDA approval for a label expansion of its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify HR-positive, HER2-ultralow metastatic breast cancer patients who may be eligible for treatment with ENHERTU. 

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
39
2
EXECUTIVE SUMMARY
 
 
 
 
 
44
3
PREMIUM INSIGHTS
 
 
 
 
 
49
4
MARKET OVERVIEW
Digital pathology demand surges as cancer cases rise, unlocking opportunities in emerging markets.
 
 
 
 
 
53
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
RISING INCIDENCE OF CANCER
 
 
 
 
 
 
4.2.1.2
GROWING DEMAND FOR DIGITAL PATHOLOGY
 
 
 
 
 
 
4.2.1.3
INCREASING HEALTHCARE EXPENDITURE
 
 
 
 
 
 
4.2.1.4
GROWING AVAILABILITY OF REIMBURSEMENTS
 
 
 
 
 
 
4.2.1.5
RISING ESTABLISHMENT OF PRIVATE DIAGNOSTIC CENTERS
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
HIGH COST OF TISSUE DIAGNOSTIC SYSTEMS
 
 
 
 
 
 
4.2.2.2
STRINGENT REGULATORY REQUIREMENTS
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
HIGH GROWTH POTENTIAL IN EMERGING ECONOMIES
 
 
 
 
 
 
4.2.3.2
GROWING PREFERENCE FOR PERSONALIZED MEDICINES
 
 
 
 
 
 
4.2.3.3
INCREASING NUMBER OF CLINICAL TRIALS FOR CANCER THERAPEUTICS
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
SHORTAGE OF SKILLED PROFESSIONALS
 
 
 
 
 
 
4.2.4.2
AVAILABILITY OF REFURBISHED PRODUCTS
 
 
 
 
 
 
4.2.4.3
INADEQUATE STANDARDIZATION
 
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
 
 
 
4.3.1
UNMET NEEDS
 
 
 
 
 
 
4.3.2
WHITE SPACE OPPORTUNITIES
 
 
 
 
 
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
 
4.4.1
CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
 
 
 
 
 
5
INDUSTRY TRENDS
Navigate competitive pressures and pricing shifts to capitalize on emerging industry opportunities.
 
 
 
 
 
66
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.2
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.3
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.4
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
 
5.3
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.5
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.6
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.6.1
AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023–2025
 
 
 
 
 
 
5.6.2
AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025
 
 
 
 
 
 
5.6.3
AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025
 
 
 
 
 
5.7
TRADE ANALYSIS
 
 
 
 
 
 
 
 
5.7.1
IMPORT DATA (HS CODE 3822)
 
 
 
 
 
 
5.7.2
EXPORT DATA (HS CODE 3822)
 
 
 
 
 
5.8
KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
 
 
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
 
5.10
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
5.11
CASE STUDY ANALYSIS
 
 
 
 
 
 
 
5.11.1
CASE STUDY 1: OPTIMIZING AUTOMATED TISSUE PROCESSING EFFICIENCY TO REDUCE COST
 
 
 
 
 
 
5.11.2
CASE STUDY 2: OPERATIONAL EFFICIENCY IMPROVEMENTS THROUGH MILESTONE MEDICAL TISSUE PROCESSOR IMPLEMENTATION
 
 
 
 
 
 
5.11.3
CASE STUDY 3: WORKFLOW OPTIMIZATION THROUGH EXCELSIOR AS TISSUE PROCESSOR
 
 
 
 
 
5.12
IMPACT OF 2025 US TARIFFS ON TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 
 
 
5.12.1
INTRODUCTION
 
 
 
 
 
 
5.12.2
KEY TARIFF RATES
 
 
 
 
 
 
5.12.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.12.4
KEY IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
 
5.12.4.1
NORTH AMERICA
 
 
 
 
 
 
5.12.4.2
EUROPE
 
 
 
 
 
 
5.12.4.3
ASIA PACIFIC
 
 
 
 
 
5.12.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
5.12.5.1
HOSPITALS
 
 
 
 
 
 
5.12.5.2
RESEARCH LABORATORIES
 
 
 
 
 
 
5.12.5.3
PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
5.12.5.4
CONTRACT RESEARCH ORGANIZATIONS (CROS)
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven diagnostics and eco-efficient innovations revolutionize tissue analysis, enhancing market adoption and sustainability.
 
 
 
 
 
86
 
6.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1
IMMUNOHISTOCHEMISTRY (IHC)
 
 
 
 
 
 
6.1.2
IN SITU HYBRIDIZATION (ISH)
 
 
 
 
 
 
6.1.3
DIGITAL PATHOLOGY
 
 
 
 
 
6.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.2.1
SPECIAL STAINING
 
 
 
 
 
 
6.2.2
MASS SPECTROMETRY IMAGING (MSI)
 
 
 
 
 
6.3
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
 
6.3.1
SHORT-TERM (2025–2027) | OPTIMIZATION & STANDARDIZATION OF CORE REAGENTS
 
 
 
 
 
 
 
6.3.1.1
CORE TECHNOLOGY DEVELOPMENT
 
 
 
 
 
 
6.3.1.2
PRODUCT INNOVATIONS
 
 
 
 
 
 
6.3.1.3
MARKET ADOPTION
 
 
 
 
 
6.3.2
MID-TERM (2027–2030) | EXPANDED CAPABILITIES & SUSTAINABILITY
 
 
 
 
 
 
 
6.3.2.1
ADVANCED TECHNOLOGY DEVELOPMENT
 
 
 
 
 
 
6.3.2.2
PRODUCT INNOVATIONS
 
 
 
 
 
 
6.3.2.3
MARKET ADOPTION
 
 
 
 
 
6.3.3
LONG-TERM (2030–2035+) | HIGH-PERFORMANCE & ECO-EFFICIENT TISSUE DIAGNOSTICS PRODUCTS
 
 
 
 
 
 
 
6.3.3.1
HIGH-PERFORMANCE & INTEGRATED WORKFLOWS
 
 
 
 
 
 
6.3.3.2
PRODUCT INNOVATIONS
 
 
 
 
 
 
6.3.3.3
MARKET ADOPTION
 
 
 
 
6.4
PATENT ANALYSIS
 
 
 
 
 
 
 
6.5
FUTURE APPLICATIONS
 
 
 
 
 
 
6.6
IMPACT OF AI/GENERATIVE AI ON TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 
 
 
6.6.1
TOP USE CASES AND MARKET POTENTIAL
 
 
 
 
 
 
6.6.2
BEST PRACTICES IN TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 
6.6.3
CASE STUDIES OF AI IMPLEMENTATION IN TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 
6.6.4
FUTURE OF AI IN TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 
6.6.5
INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS
 
 
 
 
 
 
6.6.6
CLIENTS’ READINESS TO ADOPT GENERATIVE AND AI-ENABLED TECHNOLOGIES IN TISSUE DIAGNOSTICS MARKET
 
 
 
 
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
Navigate complex regulations to drive eco-friendly innovations in tissue diagnostics globally.
 
 
 
 
 
97
 
7.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.2
INDUSTRY STANDARDS
 
 
 
 
 
7.2
SUSTAINABILITY INITIATIVES
 
 
 
 
 
 
 
7.2.1
ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN TISSUE DIAGNOSTICS
 
 
 
 
 
 
 
7.2.1.1
ECO-FRIENDLY INITIATIVES
 
 
 
 
7.3
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
 
 
 
 
 
 
7.4
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
 
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock buyer insights to navigate stakeholder influence and capitalize on unmet industry needs.
 
 
 
 
 
103
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.2.2
BUYING CRITERIA
 
 
 
 
 
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
 
 
8.5
MARKET PROFITABILITY
 
 
 
 
 
 
 
8.5.1
REVENUE POTENTIAL
 
 
 
 
 
 
8.5.2
COST DYNAMICS
 
 
 
 
 
 
8.5.3
MARGIN OPPORTUNITIES IN KEY APPLICATIONS
 
 
 
 
9
TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 160 Data Tables
 
 
 
 
 
108
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
CONSUMABLES
 
 
 
 
 
 
 
9.2.1
ANTIBODIES
 
 
 
 
 
 
 
9.2.1.1
PRIMARY ANTIBODIES
 
 
 
 
 
 
 
 
9.2.1.1.1
EXPANDING CLINICAL APPLICATIONS AND BIOMARKER DISCOVERY TO DRIVE MARKET
 
 
 
 
9.2.1.2
SECONDARY ANTIBODIES
 
 
 
 
 
 
 
 
9.2.1.2.1
RISING ADOPTION OF DIGITAL PATHOLOGY TO BOOST MARKET
 
 
 
9.2.2
KITS
 
 
 
 
 
 
 
9.2.2.1
HUMAN IMMUNOHISTOCHEMISTRY KITS
 
 
 
 
 
 
 
 
9.2.2.1.1
EXPANDING CANCER SCREENING AND BIOMARKER TESTING TO FUEL MARKET
 
 
 
 
9.2.2.2
ANIMAL IMMUNOHISTOCHEMISTRY KITS
 
 
 
 
 
 
 
 
9.2.2.2.1
GROWING PRECLINICAL AND COMPARATIVE STUDIES TO PROPEL MARKET
 
 
 
9.2.3
REAGENTS
 
 
 
 
 
 
 
9.2.3.1
BLOCKING SERA AND REAGENTS
 
 
 
 
 
 
 
 
9.2.3.1.1
RISING EMPHASIS ON DIAGNOSTIC ACCURACY TO SUPPORT GROWTH
 
 
 
 
9.2.3.2
CHROMOGENIC SUBSTRATES
 
 
 
 
 
 
 
 
9.2.3.2.1
INCREASING DEMAND FOR HIGH-SENSITIVITY CHROMOGENIC SUBSTRATES TO FUEL MARKET
 
 
 
 
9.2.3.3
FIXATION REAGENTS
 
 
 
 
 
 
 
 
9.2.3.3.1
GROWING EMPHASIS ON TISSUE INTEGRITY AND BIOMARKER PRESERVATION TO DRIVE MARKET
 
 
 
 
9.2.3.4
ORGANIC SOLVENTS
 
 
 
 
 
 
 
 
9.2.3.4.1
INCREASING FOCUS ON SOLVENT SAFETY AND EFFICIENCY TO SPUR GROWTH
 
 
 
 
9.2.3.5
PROTEOLYTIC ENZYMES
 
 
 
 
 
 
 
 
9.2.3.5.1
NEED FOR HANDLING COMPLEX TISSUE SAMPLES AND MULTIPLEXED BIOMARKER PANELS TO FACILITATE GROWTH
 
 
 
 
9.2.3.6
DILUENTS
 
 
 
 
 
 
 
 
9.2.3.6.1
RISING FOCUS ON MAINTAINING REAGENT STABILITY TO SUPPORT GROWTH
 
 
 
 
9.2.3.7
OTHER REAGENTS
 
 
 
 
 
9.2.4
PROBES
 
 
 
 
 
 
 
9.2.4.1
UTILIZATION OF PROBES IN FLUORESCENCE MICROSCOPY APPLICATIONS TO BOOST MARKET
 
 
 
 
9.3
INSTRUMENTS
 
 
 
 
 
 
 
9.3.1
SLIDE-STAINING SYSTEMS
 
 
 
 
 
 
 
9.3.1.1
H&E STAINERS
 
 
 
 
 
 
 
 
9.3.1.1.1
INCREASING PATIENT VOLUME TO SUSTAIN GROWTH
 
 
 
 
9.3.1.2
SPECIAL STAINERS
 
 
 
 
 
 
 
 
9.3.1.2.1
GROWING DEMAND FOR TARGETED VISUALIZATION TO FUEL MARKET
 
 
 
 
9.3.1.3
IHC STAINERS
 
 
 
 
 
 
 
 
9.3.1.3.1
GROWING DEMAND FOR HIGH-THROUGHPUT TISSUE ANALYSIS AND MULTIPLEX BIOMARKER PANELS TO DRIVE MARKET
 
 
 
9.3.2
MICROTOMES
 
 
 
 
 
 
 
9.3.2.1
INCREASING DEMAND FOR ACCURATE TISSUE SECTIONING TO SUPPORT GROWTH
 
 
 
 
 
9.3.3
DIGITAL PATHOLOGY SCANNERS
 
 
 
 
 
 
 
9.3.3.1
GROWING ADOPTION OF DIGITAL IMAGING TO PROPEL MARKET
 
 
 
 
 
9.3.4
TISSUE PROCESSING SYSTEMS
 
 
 
 
 
 
 
9.3.4.1
RISING NEED FOR AUTOMATION IN TISSUE PREPARATION TO PROPEL MARKET
 
 
 
 
 
9.3.5
OTHER INSTRUMENTS
 
 
 
 
 
9.4
SOFTWARE
 
 
 
 
 
 
 
9.4.1
INCREASING WORKFLOW DIGITIZATION AND DATA MANAGEMENT NEEDS TO DRIVE MARKET
 
 
 
 
 
9.5
SERVICES
 
 
 
 
 
 
 
9.5.1
RISING ADOPTION OF COMPANION DIAGNOSTICS TO EXPEDITE GROWTH
 
 
 
 
10
TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 21 Data Tables
 
 
 
 
 
175
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
IMMUNOHISTOCHEMISTRY
 
 
 
 
 
 
 
10.2.1
RISING UPTAKE OF IMMUNOHISTOCHEMISTRY KITS FOR DIAGNOSTIC APPLICATIONS TO FUEL MARKET
 
 
 
 
 
10.3
IN SITU HYBRIDIZATION
 
 
 
 
 
 
 
10.3.1
ABILITY TO DETECT SPECIFIC RNA AND DNA SEQUENCES TO BOOST MARKET
 
 
 
 
 
10.4
DIGITAL PATHOLOGY
 
 
 
 
 
 
 
10.4.1
RISING NEED FOR ANALYSIS AND SEAMLESS MANAGEMENT TO SUPPORT GROWTH
 
 
 
 
 
10.5
SPECIAL STAINING
 
 
 
 
 
 
 
10.5.1
UTILIZATION OF SPECIAL STAINING IN CANCER DIAGNOSTICS TO PROPEL MARKET
 
 
 
 
11
TISSUE DIAGNOSTICS MARKET, BY DISEASE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 37 Data Tables
 
 
 
 
 
187
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
BREAST CANCER
 
 
 
 
 
 
 
11.2.1
RISING UPTAKE OF HER2 TESTS FOR CANCER DIAGNOSIS TO FUEL MARKET
 
 
 
 
 
11.3
GASTRIC CANCER
 
 
 
 
 
 
 
11.3.1
RISING INCIDENCE OF GASTROINTESTINAL CANCER TO BOOST MARKET
 
 
 
 
 
11.4
LYMPHOMA
 
 
 
 
 
 
 
11.4.1
RISING INCIDENCE OF NON-HODGKIN’S LYMPHOMA IN ADULTS TO SUPPORT GROWTH
 
 
 
 
 
11.5
PROSTATE CANCER
 
 
 
 
 
 
 
11.5.1
GROWING RATE OF PROSTATE CANCER TO PROPEL MARKET
 
 
 
 
 
11.6
NON-SMALL CELL LUNG CANCER
 
 
 
 
 
 
 
11.6.1
GROWING FOCUS ON DEVELOPING COMPANION DIAGNOSTIC TESTS TO DRIVE MARKET
 
 
 
 
 
11.7
OTHER DISEASE TYPES
 
 
 
 
 
12
US: NUMBER OF TISSUE DIAGNOSTICS TESTS, BY SAMPLE TYPE
| 1 Data Tables
 
 
 
 
 
205
13
TISSUE DIAGNOSTICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 27 Data Tables
 
 
 
 
 
206
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
HOSPITALS
 
 
 
 
 
 
 
13.2.1
INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS TO DRIVE MARKET
 
 
 
 
 
13.3
RESEARCH LABORATORIES
 
 
 
 
 
 
 
13.3.1
RISING DEMAND OF SPECIALTY TESTS TO DRIVE MARKET
 
 
 
 
 
13.4
PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
 
13.4.1
INCREASING R&D ACTIVITIES FOR DISEASE DIAGNOSTICS TO DRIVE MARKET
 
 
 
 
 
13.5
CONTRACT RESEARCH ORGANIZATIONS
 
 
 
 
 
 
 
13.5.1
GROWING DEMAND FOR OUTSOURCING ANALYTICAL TESTING & CLINICAL TRIAL SERVICES TO BOOST MARKET
 
 
 
 
 
13.6
OTHER END USERS
 
 
 
 
 
14
TISSUE DIAGNOSTICS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 12 Countries | 217 Data Tables.
 
 
 
 
 
219
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
NORTH AMERICA
 
 
 
 
 
 
 
14.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
 
 
14.2.2
US
 
 
 
 
 
 
 
14.2.2.1
HIGH HEALTHCARE EXPENDITURE TO DRIVE MARKET
 
 
 
 
 
14.2.3
CANADA
 
 
 
 
 
 
 
14.2.3.1
RISING PREVALENCE OF CANCER TO FUEL MARKET
 
 
 
 
14.3
EUROPE
 
 
 
 
 
 
 
14.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
 
 
14.3.2
GERMANY
 
 
 
 
 
 
 
14.3.2.1
FAVORABLE GOVERNMENT INITIATIVES TO BOOST MARKET
 
 
 
 
 
14.3.3
FRANCE
 
 
 
 
 
 
 
14.3.3.1
INCREASING DEMAND FOR CANCER DIAGNOSTICS TO PROPEL MARKET
 
 
 
 
 
14.3.4
UK
 
 
 
 
 
 
 
14.3.4.1
RISING INVESTMENTS IN CANCER RESEARCH TO DRIVE MARKET
 
 
 
 
 
14.3.5
ITALY
 
 
 
 
 
 
 
14.3.5.1
HIGH INCIDENCE OF CANCER AND GERIATRIC POPULATION TO SUPPORT GROWTH
 
 
 
 
 
14.3.6
SPAIN
 
 
 
 
 
 
 
14.3.6.1
INCREASING CANCER CASES TO BOOST MARKET
 
 
 
 
 
14.3.7
REST OF EUROPE
 
 
 
 
 
14.4
ASIA PACIFIC
 
 
 
 
 
 
 
14.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
 
 
14.4.2
CHINA
 
 
 
 
 
 
 
14.4.2.1
INCREASING FOCUS ON HEALTHCARE INFRASTRUCTURE TO BOOST MARKET
 
 
 
 
 
14.4.3
JAPAN
 
 
 
 
 
 
 
14.4.3.1
RISE IN DEVELOPMENT OF ADVANCED DIAGNOSTIC PRODUCTS TO FUEL MARKET
 
 
 
 
 
14.4.4
INDIA
 
 
 
 
 
 
 
14.4.4.1
PRESENCE OF LARGE PATIENT POOL AND RAPDILY GROWING HEALTHCARE SECTOR TO DRIVE MARKET
 
 
 
 
 
14.4.5
REST OF ASIA PACIFIC
 
 
 
 
 
14.5
LATIN AMERICA
 
 
 
 
 
 
 
14.5.1
MACROEOCNOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
 
 
14.5.2
BRAZIL
 
 
 
 
 
 
 
14.5.2.1
INCREASING BURDEN OF CANCER CASES TO AID GROWTH
 
 
 
 
 
14.5.3
MEXICO
 
 
 
 
 
 
 
14.5.3.1
GROWING CANCER BURDEN TO BOOST MARKET
 
 
 
 
 
14.5.4
REST OF LATIN AMERICA
 
 
 
 
 
14.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
14.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
 
 
 
 
15
COMPETITIVE LANDSCAPE
Uncover strategic shifts and market dominance tactics shaping the competitive landscape through 2025.
 
 
 
 
 
315
 
15.1
OVERVIEW
 
 
 
 
 
 
15.2
KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2025
 
 
 
 
 
 
15.3
REVENUE ANALYSIS, 2022–2024
 
 
 
 
 
 
 
15.4
MARKET SHARE ANALYSIS, 2024
 
 
 
 
 
 
 
15.5
BRAND COMPARISON
 
 
 
 
 
 
 
15.6
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 
 
 
 
 
 
 
 
15.6.1
STARS
 
 
 
 
 
 
15.6.2
EMERGING LEADERS
 
 
 
 
 
 
15.6.3
PERVASIVE PLAYERS
 
 
 
 
 
 
15.6.4
PARTICIPANTS
 
 
 
 
 
 
15.6.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
 
 
 
 
 
 
 
15.6.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
15.6.5.2
REGION FOOTPRINT
 
 
 
 
 
 
15.6.5.3
PRODUCT & SERVICE FOOTPRINT
 
 
 
 
 
 
15.6.5.4
TECHNOLOGY FOOTPRINT
 
 
 
 
 
 
15.6.5.5
END-USER FOOTPRINT
 
 
 
 
15.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 
 
 
 
 
 
 
 
15.7.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
15.7.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
15.7.3
DYNAMIC COMPANIES
 
 
 
 
 
 
15.7.4
STARTING BLOCKS
 
 
 
 
 
 
15.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 
 
 
 
 
 
 
15.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
15.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
15.8
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
 
 
15.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
15.9.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
 
 
15.9.2
DEALS
 
 
 
 
 
 
15.9.3
EXPANSIONS
 
 
 
 
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
334
 
16.1
KEY PLAYERS
 
 
 
 
 
 
 
16.1.1
F. HOFFMANN-LA ROCHE LTD.
 
 
 
 
 
 
 
16.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
16.1.1.2
PRODUCTS OFFERED
 
 
 
 
 
 
16.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
16.1.1.3.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
16.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
16.1.1.4.1
KEY STRENGTHS/RIGHT TO WIN
 
 
 
 
 
 
16.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
16.1.1.4.3
WEAKNESSES/COMPETITIVE THREATS
 
 
 
16.1.2
DANAHER CORPORATION
 
 
 
 
 
 
16.1.3
AGILENT TECHNOLOGIES, INC.
 
 
 
 
 
 
16.1.4
PHC HOLDINGS CORPORATION (EPREDIA)
 
 
 
 
 
 
16.1.5
MERCK KGAA
 
 
 
 
 
 
16.1.6
ABBOTT
 
 
 
 
 
 
16.1.7
BECTON, DICKINSON AND COMPANY
 
 
 
 
 
 
16.1.8
SYSMEX CORPORATION
 
 
 
 
 
 
16.1.9
SAKURA FINETEK JAPAN CO., LTD.
 
 
 
 
 
 
16.1.10
BIOGENEX
 
 
 
 
 
 
16.1.11
BIO SB
 
 
 
 
 
 
16.1.12
CELL SIGNALING TECHNOLOGY, INC.
 
 
 
 
 
 
16.1.13
HISTO-LINE LABORATORIES
 
 
 
 
 
 
16.1.14
SLEE MEDICAL GMBH
 
 
 
 
 
16.2
OTHER PLAYERS
 
 
 
 
 
 
 
16.2.1
AMOS SCIENTIFIC PTY LTD.
 
 
 
 
 
 
16.2.2
JINHUA YIDI MEDICAL APPLIANCE CO., LTD.
 
 
 
 
 
 
16.2.3
MEDITE MEDICAL GMBH
 
 
 
 
 
 
16.2.4
SLMP, LLC
 
 
 
 
 
 
16.2.5
KONFOONG BIOINFORMATION TECH CO., LTD (KFBIO)
 
 
 
 
 
 
16.2.6
DIAGNOSTIC BIOSYSTEMS INC.
 
 
 
 
 
 
16.2.7
3DHISTECH LTD.
 
 
 
 
 
 
16.2.8
RWD LIFE SCIENCE CO., LTD.
 
 
 
 
 
 
16.2.9
DAKEWE
 
 
 
 
 
 
16.2.10
BATTERY VENTURES (ENZO BIOCHEM INC.)
 
 
 
 
 
 
16.2.11
BIOCARE MEDICAL, LLC.
 
 
 
 
 
 
16.2.12
MILESTONE SRL
 
 
 
 
 
 
16.2.13
BIO-OPTICA MILANO SPA
 
 
 
 
 
 
16.2.14
BIOGNOST D.O.O.
 
 
 
 
 
 
16.2.15
OPTRASCAN
 
 
 
 
 
 
16.2.16
CLARAPATH
 
 
 
 
17
RESEARCH METHODOLOGY
 
 
 
 
 
397
 
17.1
RESEARCH DATA
 
 
 
 
 
 
 
17.1.1
SECONDARY DATA
 
 
 
 
 
 
 
17.1.1.1
KEY DATA FROM SECONDARY SOURCES
 
 
 
 
 
17.1.2
PRIMARY DATA
 
 
 
 
 
 
 
17.1.2.1
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
 
 
17.1.2.2
KEY PRIMARY PARTICIPANTS
 
 
 
 
 
 
17.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
 
 
17.1.2.4
KEY INDUSTRY INSIGHTS
 
 
 
 
17.2
MARKET SIZE ESTIMATION
 
 
 
 
 
 
 
17.2.1
BOTTOM-UP APPROACH
 
 
 
 
 
 
 
17.2.1.1
REVENUE ESTIMATION OF KEY PLAYERS
 
 
 
 
 
 
17.2.1.2
STUDY OF ANNUAL REPORTS AND INVESTOR PRESENTATIONS
 
 
 
 
 
 
17.2.1.3
PRIMARY INTERVIEWS
 
 
 
 
 
 
17.2.1.4
GROWTH FORECAST
 
 
 
 
 
17.2.2
TOP-DOWN APPROACH
 
 
 
 
 
 
17.2.3
BASE NUMBER CALCULATION
 
 
 
 
 
17.3
MARKET FORECAST APPROACH
 
 
 
 
 
 
17.4
DATA TRIANGULATION
 
 
 
 
 
 
17.5
FACTOR ANALYSIS
 
 
 
 
 
 
17.6
RESEARCH ASSUMPTIONS
 
 
 
 
 
 
 
17.6.1
PARAMETRIC ASSUMPTIONS
 
 
 
 
 
 
17.6.2
GROWTH RATE ASSUMPTIONS
 
 
 
 
 
17.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
 
 
 
 
 
 
 
17.7.1
RESEARCH LIMITATIONS
 
 
 
 
 
 
17.7.2
RISK ASSESSMENT
 
 
 
 
18
APPENDIX
 
 
 
 
 
412
 
18.1
DISCUSSION GUIDE
 
 
 
 
 
 
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
18.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
18.4
RELATED REPORTS
 
 
 
 
 
 
18.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
PROJECTED INCREASE IN CANCER PATIENTS, 2022 VS. 2035 VS. 2050, BY REGION
 
 
 
 
 
 
 
PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, BY TYPE,
 
 
 
 
 
 
2022
VS. 2045
 
 
 
 
 
55
TABLE 3
INTERCONNECTED MARKETS
 
 
 
 
 
 
TABLE 4
KEY MOVES AND STRATEGIC FOCUS
 
 
 
 
 
 
TABLE 5
IMPACT OF PORTER’S FORCES ON TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 
TABLE 6
GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
 
 
 
 
 
 
TABLE 7
NORTH AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 8
EUROPE: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 9
ASIA PACIFIC: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 10
LATIN AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 11
MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 12
TISSUE DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
 
 
 
 
 
 
TABLE 13
AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 14
AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 15
AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 16
IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION)
 
 
 
 
 
 
TABLE 17
EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION)
 
 
 
 
 
 
TABLE 18
TISSUE DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
 
 
TABLE 19
US-ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
 
 
TABLE 20
TISSUE DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS, 2023–2025
 
 
 
 
 
 
TABLE 21
CLIENT’S READINESS TO ADOPT AI AND GENERATIVE TECHNOLOGIES IN TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 
TABLE 22
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 23
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 24
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 25
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 26
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 27
TISSUE DIAGNOSTICS MARKET: GLOBAL STANDARDS
 
 
 
 
 
 
TABLE 28
TISSUE DIAGNOSTICS MARKET: CERTIFICATIONS, LABELING, AND ECO-STANDARDS
 
 
 
 
 
 
TABLE 29
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
 
 
 
 
 
 
TABLE 30
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
 
TABLE 31
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
TABLE 32
TISSUE DIAGNOSTICS MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
 
 
TABLE 33
TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 34
TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 35
TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 36
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 37
EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 38
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 39
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 40
TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 41
TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 42
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 43
EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 44
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 45
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 46
PRIMARY ANTIBODIES AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 47
TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 48
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 49
EUROPE: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 50
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 51
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 52
SECONDARY ANTIBODIES AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 53
TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 54
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 55
EUROPE: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 56
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 57
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 58
TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 59
TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 60
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 61
EUROPE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 62
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 63
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 64
HUMAN IMMUNOHISTOCHEMISTRY KITS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 65
TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 66
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 67
EUROPE: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 68
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 69
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 70
ANIMAL IMMUNOHISTOCHEMISTRY KITS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 71
TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 72
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 73
EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 74
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 75
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 76
TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 77
TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 78
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 79
EUROPE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 80
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 81
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 82
BLOCKING SERA & REAGENTS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 83
TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 84
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 85
EUROPE: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 86
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 87
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 88
CHROMOGENIC SUBSTRATES AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 89
TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 90
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 91
EUROPE: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 92
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 93
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 94
FIXATION REAGENTS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 95
TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 96
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 97
EUROPE: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 98
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 99
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 100
TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 101
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 102
EUROPE: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 103
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 104
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 105
PROTEOLYTIC ENZYMES AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 106
TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 107
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 108
EUROPE: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 109
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 110
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 111
DILUENTS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 112
TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 113
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 114
EUROPE: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 115
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 116
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 117
OTHER REAGENTS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 118
TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 119
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 120
EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 121
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 122
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 123
PROBES AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 124
TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 125
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 126
EUROPE: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 127
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 128
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 129
TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 130
TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 131
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 132
EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 133
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 134
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 135
TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 136
TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 137
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 138
EUROPE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 139
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 140
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 141
H&E STAINERS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 142
TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 143
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 144
EUROPE: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 145
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 146
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 147
SPECIAL STAINERS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 148
TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 149
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 150
EUROPE: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 151
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 152
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, Y COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 153
IHC STAINERS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 154
TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 155
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 156
EUROPE: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 157
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 158
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 159
MICROTOMES AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 160
TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 161
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 162
EUROPE: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 163
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 164
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 165
DIGITAL PATHOLOGY SCANNERS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 166
TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 167
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 168
EUROPE: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 169
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 170
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 171
TISSUE PROCESSING SYSTEMS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 172
TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 173
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 174
EUROPE: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 175
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 176
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 177
OTHER INSTRUMENTS AVAILABLE IN MARKET
 
 
 
 
 
 
TABLE 178
TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 179
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 180
EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 181
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 182
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 183
TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 184
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 185
EUROPE: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 186
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 187
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 188
TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 189
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 190
EUROPE: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 191
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 192
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 193
TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 194
TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 195
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 196
EUROPE: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 197
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 198
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 199
TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 200
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 201
EUROPE: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 202
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 203
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 204
TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 205
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 206
EUROPE: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 207
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 208
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 209
TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 210
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 211
EUROPE: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 212
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 213
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 214
GLOBAL CANCER INCIDENCE, 2020 VS. 2040
 
 
 
 
 
 
TABLE 215
TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 216
BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
 
 
 
 
 
 
TABLE 217
TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 218
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 219
EUROPE: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 220
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 221
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 222
COLON CANCER INCIDENCE, BY REGION, 2020 VS. 2040
 
 
 
 
 
 
TABLE 223
TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 224
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 225
EUROPE: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 226
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 227
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 228
HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
 
 
 
 
 
 
TABLE 229
NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
 
 
 
 
 
 
TABLE 230
TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 231
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 232
EUROPE: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 233
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 234
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 235
PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
 
 
 
 
 
 
TABLE 236
TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 237
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 238
EUROPE: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 239
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 240
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 241
TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 242
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 243
EUROPE: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 244
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 245
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 246
TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 247
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 248
EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 249
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 250
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 251
US: NUMBER OF TISSUE DIAGNOSTICS TESTS, BY SAMPLE TYPE, 2023–2030 (NO. OF TESTS)
 
 
 
 
 
 
TABLE 252
TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 253
TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 254
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 255
EUROPE: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 256
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 257
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 258
TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 259
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 260
EUROPE: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 261
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 262
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 263
TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 264
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 265
EUROPE: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 266
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 267
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 268
CONTRACT RESEARCH ORGANIZATIONS FOR ONCOLOGY DIAGNOSTICS
 
 
 
 
 
 
TABLE 269
TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 270
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 271
EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 272
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 273
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 274
TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 275
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 276
EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 277
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 278
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 279
TISSUE DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 280
NORTH AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 281
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 282
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 283
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 284
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 285
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 286
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 287
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 288
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 289
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 290
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 291
NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 292
US CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
 
 
 
 
 
 
TABLE 293
US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 294
US: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 295
US: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 296
US: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 297
US: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 298
US: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 299
US: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 300
US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 301
US: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 302
US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 303
CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
 
 
 
 
 
 
TABLE 304
CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 305
CANADA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 306
CANADA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 307
CANADA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 308
CANADA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 309
CANADA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 310
CANADA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 311
CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 312
CANADA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 313
CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 314
EUROPE: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 315
EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 316
EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 317
EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 318
EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 319
EUROPE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 320
EUROPE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 321
EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 322
EUROPE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 323
EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 324
EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 325
EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 326
GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
 
 
 
 
 
 
TABLE 327
GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 328
GERMANY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 329
GERMANY: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 330
GERMANY: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 331
GERMANY: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 332
GERMANY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 333
GERMANY: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 334
GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 335
GERMANY: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 336
GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 337
FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
 
 
 
 
 
 
TABLE 338
FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 339
FRANCE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 340
FRANCE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 341
FRANCE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 342
FRANCE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 343
FRANCE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 344
FRANCE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 345
FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 346
FRANCE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 347
FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 348
UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 349
UK: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 350
UK: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 351
UK: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 352
UK: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 353
UK: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 354
UK: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 355
UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 356
UK: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 357
UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 358
ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
 
 
 
 
 
 
TABLE 359
ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 360
ITALY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 361
ITALY: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 362
ITALY: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 363
ITALY: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 364
ITALY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 365
ITALY: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 366
ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 367
ITALY: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 368
ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 369
SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 370
SPAIN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 371
SPAIN: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 372
SPAIN: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 373
SPAIN: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 374
SPAIN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 375
SPAIN: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 376
SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 377
SPAIN: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 378
SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 379
REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 380
REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 381
REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 382
REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 383
REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 384
REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 385
REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 386
REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 387
REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 388
REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 389
ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 390
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 391
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 392
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 393
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 394
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 395
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 396
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 397
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 398
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 399
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 400
ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 401
CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 402
CHINA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 403
CHINA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 404
CHINA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 405
CHINA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 406
CHINA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 407
CHINA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 408
CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 409
CHINA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 410
CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 411
CANCER INCIDENCE, BY CANCER TYPE (JAPAN), 2020 VS. 2040
 
 
 
 
 
 
TABLE 412
JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 413
JAPAN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 414
JAPAN: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 415
JAPAN: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 416
JAPAN: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 417
JAPAN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 418
JAPAN: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 419
JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 420
JAPAN: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 421
JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 422
INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 423
INDIA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 424
INDIA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 425
INDIA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 426
INDIA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 427
INDIA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 428
INDIA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 429
INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 430
INDIA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 431
INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 432
REST OF ASIA PACIFIC: CANCER INCIDENCE, 2020 VS. 2040
 
 
 
 
 
 
TABLE 433
REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 434
REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 435
REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 436
REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 437
REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 438
REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 439
REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 440
REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 441
REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 442
REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 443
LATIN AMERICA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 444
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 445
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 446
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 447
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 448
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 449
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 450
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 451
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 452
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 453
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 454
LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 455
BRAZIL: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 456
BRAZIL: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 457
BRAZIL: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 458
BRAZIL: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 459
BRAZIL: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 460
BRAZIL: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 461
BRAZIL: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 462
BRAZIL: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 463
BRAZIL: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 464
BRAZIL: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 465
MEXICO: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 466
MEXICO: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 467
MEXICO: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 468
MEXICO: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 469
MEXICO: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 470
MEXICO: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 471
MEXICO: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 472
MEXICO: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 473
MEXICO: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 474
MEXICO: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 475
REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 476
REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 477
REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 478
REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 479
REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 480
REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 481
REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 482
REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 483
REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 484
REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 485
MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 486
MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 487
MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 488
MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 489
MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 490
MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 491
MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 492
MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 493
MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 494
MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 495
MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 496
KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2025
 
 
 
 
 
 
TABLE 497
TISSUE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 498
REGION FOOTPRINT
 
 
 
 
 
 
TABLE 499
PRODUCT & SERVICE FOOTPRINT
 
 
 
 
 
 
TABLE 500
APPLICATION FOOTPRINT
 
 
 
 
 
 
TABLE 501
END USER FOOTPRINT
 
 
 
 
 
 
TABLE 502
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 503
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 504
TISSUE DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 505
TISSUE DIAGNOSTICS MARKET: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 506
TISSUE DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 507
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 508
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 509
F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 510
DANAHER CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 511
DANAHER CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 512
DANAHER CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 513
DANAHER CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 514
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 515
AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 516
AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 517
PHC HOLDINGS CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 518
PHC HOLDINGS CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 519
PHC HOLDINGS CORPORATION: PRODUCT APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 520
PHC HOLDINGS CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 521
MERCK KGAA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 522
MERCK KGAA: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 523
MERCK KGAA: EXPANSIONS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 524
ABBOTT: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 525
ABBOTT: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 526
BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 527
BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 528
BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 529
SYSMEX CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 530
SYSMEX CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 531
SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 532
SYSMEX CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 533
SAKURA FINETEK JAPAN CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 534
SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 535
SAKURA FINETEK JAPAN CO., LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 536
SAKURA FINETEK JAPAN CO., LTD.: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 537
SAKURA FINETEK JAPAN CO., LTD.: EXPANSIONS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 538
BIOGENEX: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 539
BIOGENEX: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 540
BIOGENEX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 541
BIO SB: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 542
BIO SB: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 543
CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 544
CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 545
CELL SIGNALING TECHNOLOGY, INC.: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 546
HISTO-LINE LABORATORIES: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 547
HISTO-LINE LABORATORIES: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 548
SLEE MEDICAL GMBH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 549
SLEE MEDICAL GMBH: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 550
AMOS SCIENTIFIC PTY LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 551
JINHUA YIDI MEDICAL APPLIANCE CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 552
MEDITE MEDICAL GMBH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 553
SLMP, LLC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 554
KONFOONG BIOINFORMATION TECH CO., LTD (KFBIO): COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 555
DIAGNOSTIC BIOSYSTEMS INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 556
3DHISTECH LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 557
RWD LIFE SCIENCE CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 558
DAKEWE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 559
BATTERY VENTURES (ENZO BIOCHEM INC.): COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 560
BIOCARE MEDICAL, LLC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 561
MILESTONE SRL: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 562
BIO-OPTICA MILANO SPA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 563
BIOGNOST D.O.O.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 564
OPTRASCAN: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 565
CLARAPATH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 566
IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS
 
 
 
 
 
 
TABLE 567
RESAERCH ASSUMPTIONS
 
 
 
 
 
 
TABLE 568
RISK ASSESSMENT
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
TISSUE DIAGNOSTICS MARKET SEGMENTATION AND REGIONAL SCOPE
 
 
 
 
 
 
FIGURE 2
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 3
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET, 2022–2025
 
 
 
 
 
 
FIGURE 4
DISRUPTIVE TRENDS IMPACTING GROWTH OF TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 
FIGURE 5
HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN TISSUE DIAGNOSTICS MARKET, 2024
 
 
 
 
 
 
FIGURE 6
ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 7
GROWING PREVALENCE OF CANCER CASES TO DRIVE MARKET
 
 
 
 
 
 
FIGURE 8
CONSUMABLES SEGMENT TO HAVE LARGEST MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 9
IMMUNOHISTOCHEMISTRY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 10
BREAST CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 11
HOSPITALS SEGMENT TO HAVE LARGEST SHARE DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 12
ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 13
TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 14
NEWLY APPROVED PERSONALIZED MEDICINES (% OF ALL NEWLY APPROVED DRUGS), 2015–2024
 
 
 
 
 
 
FIGURE 15
TISSUE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 16
TISSUE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 17
TISSUE DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 18
TISSUE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 19
TISSUE DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
 
FIGURE 20
TISSUE DIAGNOSTICS MARKET: INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
FIGURE 21
PATENT ANALYSIS FOR TISSUE PROCESSING SYSTEMS, JANUARY 2015–DECEMBER 2024
 
 
 
 
 
 
FIGURE 22
MARKET POTENTIAL OF AI IN TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 
FIGURE 23
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
 
 
 
 
 
 
FIGURE 24
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
 
FIGURE 25
NORTH AMERICA TISSUE DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 26
ASIA PACIFIC TISSUE DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 27
REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION)
 
 
 
 
 
 
FIGURE 28
MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
 
 
 
 
 
 
FIGURE 29
US MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
 
 
 
 
 
 
FIGURE 30
BRAND COMPARISON
 
 
 
 
 
 
FIGURE 31
TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
 
 
FIGURE 32
COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 33
TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
 
 
FIGURE 34
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 35
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 36
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 37
DANAHER CORPORATION: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 38
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 39
PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 40
MERCK KGAA: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 41
ABBOTT: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 42
BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 43
SYSMEX CORPORATION: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 44
TISSUE DIAGNOSTICS MARKET: RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 45
TISSUE DIAGNOTICS MARKET: KEY DATA FROM SECONDARY SOURCES
 
 
 
 
 
 
FIGURE 46
LIST OF PRIMARY SOURCES IN TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 
FIGURE 47
TISSUE DIAGNOSTICS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
 
 
FIGURE 48
TISSUE DIAGNOSTICS MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS
 
 
 
 
 
 
FIGURE 49
REVENUE ESTIMATION OF KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 
FIGURE 50
TISSUE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 51
TISSUE DIAGNOSTICS BASE NUMBER CALCULATION (SUPPLY-SIDE ANALYSIS), 2024
 
 
 
 
 
 
FIGURE 52
TISSUE DIAGNOSTICSMARKET MARKET: CAGR PROJECTIONS
 
 
 
 
 
 
FIGURE 53
TISSUE DIAGNOSTICS MARKET: DATA TRIANGULATION
 
 
 
 
 
 
FIGURE 54
PARAMETRIC ASSUMPTIONS IN TISSUE DIAGNOSTICS MARKET
 
 
 
 
 
 

Methodology

The study involved major activities in estimating the current market size for the global tissue diagnostics market.

Exhaustive secondary research was done to collect information on the global tissue diagnostics market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the global tissue diagnostics market.

Four steps involved in estimating the market size are as follows:/p>

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry's value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

Tissue Diagnostics Market Size, and Share

Note 1: Others include Sales Managers, Marketing Managers, and Product Managers.

Note 2: Companies are classified into tiers based on their total revenue. Here's the breakdown of tiers:

Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both the top-down and bottom-up approaches were used to estimate and validate the global tissue diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:

  • The key players in the industry have been identified through extensive secondary research.
  • The revenues generated by leading players operating in the tissue diagnostics market have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

The research methodology used to estimate the market size included the following:

Tissue Diagnostics Market : Top-Down and Bottom-Up Approach

Tissue Diagnostics Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Tissue-based diagnostic tests are performed for screening, diagnosing, and monitoring the response of cancer patients to therapy. Tissue diagnosis refers to the examination of intact tissues obtained during a medical procedure, such as biopsies and surgeries. Tissue-based diagnostic tests are used in the treatment of breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, and other diseases (bone cancer, cervical cancer, colon cancer, cervix cancer, gallbladder carcinoma, skin cancer, HBV, Epstein-Barr virus, hepatitis, and muscular dystrophies). These diagnostic tests are carried out to identify a medical condition in its early stage so as to establish the correct course of treatment. Tissue diagnostic tests are also carried out to determine the course of recovery and response to the treatment.

Key Stakeholders

  • Senior Management
  • End Users
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global tissue diagnostics market by product & service, technology, disease type, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the global tissue diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the global tissue diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
  • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

Customization Options:

MarketsandMarkets offers the following customizations for this market report.

Country Information

  • Additional country-level analysis of the global tissue diagnostics market Company profiles

Company profiles

  • Additional five company profiles of players operating in the global tissue diagnostics market
  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the global tissue diagnostics market

 

 

Table of Contents

Methodology

 Request Customization Speak to Analyst
Speak to Analyst
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Tissue Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Tissue Diagnostics Market

avtar

Henry

Apr, 2026

We are involved in IVD manufacturing. How is demand evolving for raw materials like reagents and antibodies?.

avtar

Miles

Apr, 2026

How is next-generation sequencing (NGS) influencing advancements in tissue diagnostics and precision medicine workflows?.

avtar

Zayden

Apr, 2026

With digital pathology and AI integration gaining traction, what are the biggest barriers labs face when transitioning from conventional tissue diagnostics workflows?.

avtar

Kaelix

Apr, 2026

From a buyer’s perspective, how should hospitals justify the high upfront costs of automated staining systems and digital scanners?.

avtar

Brynlee

Apr, 2026

Given that consumables dominate revenue in this market, how sustainable is this model for suppliers in the long run?.

avtar

Jovian

Apr, 2026

How scalable is tissue diagnostics adoption in emerging markets, where infrastructure and skilled personnel are limited?.

avtar

Sable

Apr, 2026

Looking ahead, where do you see the next wave of innovation and investment opportunities in tissue diagnostics?.

bottom banner
DMCA.com Protection Status
popup img